The Latest Analyst Ratings For Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
In the latest quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) received somewhat bullish ratings from 4 analysts, with an updated average 12-month price target of $92.00, marking a significant increase from the previous $57.00. The company's financial performance shows a revenue growth of 8.1% as of September 30, 2023, but it struggles with a high net margin of -162.82% and below-average ROE and ROA, indicating potential challenges in financial returns and asset utilization.

February 15, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical received somewhat bullish ratings from analysts, with a significant increase in the average 12-month price target to $92.00. The company's financial indicators show growth but also highlight challenges in profitability and asset efficiency.
The somewhat bullish analyst ratings and the significant increase in the average 12-month price target suggest a positive outlook for Ultragenyx Pharmaceutical's stock in the short term. However, the company's financial challenges, such as a high net margin of -162.82% and below-average ROE and ROA, may temper investor enthusiasm. The positive shift in analyst sentiment, combined with the company's revenue growth, indicates potential for stock appreciation, but the financial health concerns could limit the extent of short-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100